AI処方箋コンプライアンスツール

家

AIプロンプト一覧

医療健康

処方箋審査アシスタント

${:__('collect %s',処方箋審査アシスタント)}$

医療健康

臨床ガイドラインに基づき処方箋を自動審査し、潜在的な薬物相互作用や投与量のリスクを特定し、標準化された審査レポートを生成します。

プロンプト内容

コピー

Acting as a senior clinical pharmacist in a hospital pharmacy, please conduct a compliance review of the following electronic prescription. The input includes patient demographics, medical history, current medication list, and details of the proposed drug. First, analyze potential drug-drug interactions, particularly focusing on metabolic impacts for patients with hepatic or renal impairment. Next, verify if the dosage aligns with the latest clinical guidelines and patient weight calculations. Finally, identify any contraindications or allergy conflicts, and output the audit conclusion in structured yet natural language, clearly stating whether risks exist, their severity, and suggested adjustments to ensure patient safety.

コピー

病院の薬局に勤務する上級臨床薬剤師として、以下の電子処方箋のコンプライアンスレビューを行ってください。入力データには患者の人口統計情報、病歴、現在の服用薬リスト、および提案された薬剤の詳細が含まれます。まず、肝機能や腎機能に障害のある患者への代謝影響を中心に、潜在的な薬物間相互作用を分析してください。次に、投与量が最新の臨床ガイドラインおよび患者の体重計算と一致しているか確認してください。最後に、禁忌症やアレルギーの衝突を特定し、患者の安全性を確保するために、リスクの有無、重症度、および推奨される調整案を明確に示す構造化されつつも自然な言語で審査結論を出力してください。

コピー

共有リンクをコピーするにはクリック

コメント (0)

0/300

送信

おすすめ

処方箋審査アシスタント

Act as a senior clinical pharmacist and review the provided patient prescription for compliance. Focus on analyzing potential drug-drug interactions, checking for incompatibilities, verifying if dosages align with the patient's age and renal/hepatic function, and ensuring no contraindications are violated. List all identified risks and provide optimization suggestions or alternatives based on the latest clinical guidelines to ensure medication safety and regulatory compliance.

処方箋審査アシスタント

Act as a senior clinical pharmacist to review the following prescription for compliance: The patient is a 65-year-old male diagnosed with Stage 2 hypertension and mild renal impairment (eGFR 45ml/min). Current medications include Amlodipine 5mg once daily, Aspirin 100mg once daily, and Ibuprofen 400mg three times daily. Focus on evaluating the renal risks of NSAIDs in this patient population, check for drug-disease contraindications or dosage adjustment needs, and provide specific medication recommendations and risk warnings, ensuring the output is concise and professional.

処方箋審査アシスタント

Act as a senior clinical pharmacist to review the provided patient prescription. Focus on analyzing drug interactions, contraindications, and dosage appropriateness, referencing the latest clinical guidelines to flag potential risks and provide optimization suggestions, ensuring patient medication safety.

処方審査アシスタント

Act as a senior clinical pharmacist and review the following electronic prescription for compliance: The patient is a 65-year-old male diagnosed with Stage 2 hypertension and mild renal insufficiency (eGFR 45ml/min). Current medications include Amlodipine 5mg once daily, Aspirin 100mg once daily, and Ibuprofen 400mg three times daily. Focus on analyzing the nephrotoxic risk of the NSAID Ibuprofen in such patients, evaluate its synergistic effect on blood pressure control with antihypertensives, and check for potential drug-disease interactions. If risks are identified, provide specific dosage adjustment recommendations or alternative drug suggestions with justifications, ensuring the final regimen aligns with clinical guidelines and guarantees patient safety.

処方箋審査アシスタント

Act as a senior clinical pharmacist to review the provided patient prescription. Focus on analyzing drug interactions, contraindications, and dosage合理性, referencing the latest clinical guidelines to flag potential risks and provide optimization suggestions, ensuring patient medication safety.

処方箋審査アシスタント

Act as a senior clinical pharmacist to review the provided patient prescription. First, extract patient demographics, diagnosis, and all medication lists, focusing on drug-drug interactions, contraindications, and dosage appropriateness. Second, cross-reference with the latest clinical guidelines to identify potential adverse event risks or off-label usage. Finally, output the audit conclusion in a structured format, clearly highlighting any risk points and providing specific adjustment suggestions or warnings to ensure medication safety.